Grant: Operating Grant
McMaster University
$321,489.00
Are circulating fibrocytes associated with a worse renal outcome in patients with glomerulonephritis?
EF 2011-12
Résumé
Glomerulonephritis is a form of kidney injury that involves inflammation of the small filters of the kidneys (glomeruli) with associated loss of kidney function. The majority of patients can recover when treated with potent drugs that suppress the immune system. Despite treatment, some patients will continue to have a decline in kidney function which does not appear to be caused by the initial inflammation, but by a progressive scarring of the kidney tissue.
The cause of this scarring or fibrosis is not clear. One possibility is that special cells are recruited from the bone marrow (in a similar manner to the way inflammatory cells are recruited to injured tissue). These cells are called 'fibrocytes' as they appear to be similar in some respects to 'fibroblasts' that are known to cause scarring in tissues.
It is not clear whether these fibrocyte cells are good are bad. They may cause scarring in tissue, or they may be involved in healing and repair. Glomerulonephritis provides a unique opportunity to understand the role of these fibrocytes in disease.
Most patients get a kidney biopsy to diagnose the disease so we can look for the presence of these cells in the tissue and in the blood at the same time. We can see whether the number of fibrocytes predict whether the patient will recover renal function or not.
By studying the role of fibrocytes in this disease, we will gain further insights into the causes of loss of kidney function and hints that may lead us to new potential treatments.
Programme
Operating Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
252935
Name
Margetts Peter J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Clinical Investigation - C: Digestive, Endocrine and Excretory Systems
Projecttitle
Are circulating fibrocytes associated with a worse renal outcome in patients with glomerulonephritis?
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$321,489
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Bone Marrow Derived Progenitor Cells; Circulating Fibrocytes; Flow Cytometry; Glomerulonephritis; Immunohistochemistry; Tubulointerstitial Fibrosis
Abstract
Glomerulonephritis is a form of kidney injury that involves inflammation of the small filters of the kidneys (glomeruli) with associated loss of kidney function. The majority of patients can recover when treated with potent drugs that suppress the immune system. Despite treatment, some patients will continue to have a decline in kidney function which does not appear to be caused by the initial inflammation, but by a progressive scarring of the kidney tissue.
The cause of this scarring or fibrosis is not clear. One possibility is that special cells are recruited from the bone marrow (in a similar manner to the way inflammatory cells are recruited to injured tissue). These cells are called 'fibrocytes' as they appear to be similar in some respects to 'fibroblasts' that are known to cause scarring in tissues.
It is not clear whether these fibrocyte cells are good are bad. They may cause scarring in tissue, or they may be involved in healing and repair. Glomerulonephritis provides a unique opportunity to understand the role of these fibrocytes in disease.
Most patients get a kidney biopsy to diagnose the disease so we can look for the presence of these cells in the tissue and in the blood at the same time. We can see whether the number of fibrocytes predict whether the patient will recover renal function or not.
By studying the role of fibrocytes in this disease, we will gain further insights into the causes of loss of kidney function and hints that may lead us to new potential treatments.
Competitiondate
201203
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Margetts, Peter J
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $321,489~ $0~